Stress Response Pathways in Vitiligo

Launched by NYU LANGONE HEALTH · Jun 8, 2016

Keywords

ClinConnect Summary

Identifying a role for NF-κB signaling in vitiligo may improve therapies for this disfiguring disorder. Current treatments vary in effectiveness and may not always be long lasting cases. The NF-κB pathway and IL-6 itself are the target of several FDA approved drugs, thus opening new therapeutic avenues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * To be eligible for participation, subjects must meet all of the following criteria:
• • Must have a clinical exam consistent with and diagnosis of non-segmental vitiligo
• • Must be normally pigmented
• • No clinical presentation of vitiligo
• Exclusion Criteria:
• • Outside of the specified age range
• • No clinical diagnosis of vitiligo
• • Use of systemic therapies, including but not limited to methotrexate, etretinate, or cyclosporine, calcineurin inhibitors and/ or vitamin D analogs within 4 weeks of enrollment
• • Use of topical steroids or topical immunodilators at biopsy site within 4 weeks of enrollment
• • History of keloids or hypertrophic scars
• • Patients with pacemakers or defibrillators or heart valves
• • Patients on Plavix, Warfarin or similar anticoagulation medicine
• • Pregnant females
• • Lactating women
• • Allergies or sensitivity to lidocaine or epinephrine
• • Outside of the specified age range
• • Abnormally pigmented at potential biopsy sites (non-vitiligo)
• • Clinical presentation of vitiligo
• • Use of systemic therapies, including but not limited to methotrexate, etretinate, or cyclosporine, calcineuron inhibitors and/ or vitamin D analogs within 4 weeks of enrollment
• • Use of topical steroids or topical immunodilators at biopsy site within 4 weeks of enrollment
• • History of keloids or hypertrophic scars